Contact
searchSearch
HMP Global

Radiopharmaceutical Education Institute

Clinical Insights

Kim Chi, MD
Videos
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
Kim Chi, MD
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover...
06/19/2026
Radiopharmaceutical Education Institute
David Cade, MD
Videos
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
David Cade, MD
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the...
06/19/2026
Radiopharmaceutical Education Institute
Michael Morris, MD
Videos
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
06/18/2026
Michael Morris, MD
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses...
06/18/2026
Radiopharmaceutical Education Institute
Scott Tagawa, MD
Videos
Theranostics Advances in Solid Tumors
03/19/2026
Scott Tagawa, MD
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the...
03/19/2026
Oncology
Oliver Sartor, MD, East Jefferson Medical Center
Videos
Welcome to the Radiopharmaceutical Education Institute
03/11/2026
Oliver Sartor, MD
Oliver Sartor, MD, introduces the new Radiopharmaceutical Education Institute (RPEI), a platform designed to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical...
Oliver Sartor, MD, introduces the new Radiopharmaceutical Education Institute (RPEI), a platform designed to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical...
Oliver Sartor, MD, introduces...
03/11/2026
Radiopharmaceutical Education Institute
Bertrand Tombal, MD, PhD
Videos
Radium-223 Plus Enzalutamide Improves Survival in Bone-Predominant Metastatic Castration-Resistant Prostate Cancer
03/05/2026
Bertrand Tombal, MD, PhD
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD,...
03/05/2026
Radiopharmaceutical Education Institute
Alexander Wyatt, PhD
Videos
Clonal Hematopoiesis Expansion Following 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
02/26/2026
Alexander Wyatt, PhD
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses...
02/26/2026
Radiopharmaceutical Education Institute
Aman Chauhan, MD, University of Miami
Videos
Designing Early-Phase Radioligand Therapy Trials: What Makes Them Different?
02/12/2026
Aman Chauhan, MD
Aman Chauhan, MD, discusses how early-phase radioligand therapy trials differ from conventional phase 1 oncology studies by incorporating dosimetry, imaging-based biomarkers, cumulative radiation safety considerations, and additional...
Aman Chauhan, MD, discusses how early-phase radioligand therapy trials differ from conventional phase 1 oncology studies by incorporating dosimetry, imaging-based biomarkers, cumulative radiation safety considerations, and additional...
Aman Chauhan, MD, discusses how...
02/12/2026
Radiopharmaceutical Education Institute
Ana Kiess, MD, PhD, Johns Hopkins Medicine
Videos
Personalizing Theranostics: Adaptive Dosing Strategies Informed by Radiation Oncology
02/12/2026
Ana Kiess, MD, PhD
Ana Kiess, MD, PhD, Johns Hopkins Medicine, Baltimore, Maryland, discusses how lessons from external beam radiation therapy can guide adaptive dosing strategies in theranostics to improve tumor control while balancing toxicity.
Ana Kiess, MD, PhD, Johns Hopkins Medicine, Baltimore, Maryland, discusses how lessons from external beam radiation therapy can guide adaptive dosing strategies in theranostics to improve tumor control while balancing toxicity.
Ana Kiess, MD, PhD, Johns...
02/12/2026
Radiopharmaceutical Education Institute
Praful Ravi, MB, BChir, MRCP, Dana-Farber Cancer Institute
Videos
PSMA Radioligand Therapy in Hormone-Sensitive Prostate Cancer: Lessons from the PSMAddition Trial
02/12/2026
Praful Ravi, MB, BChir, MRCP
Praful Ravi, MB, BChir, MRCP, discusses the potential role of PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer, highlighting radiographic PFS benefits from the PSMAddition trial while emphasizing the need to balance...
Praful Ravi, MB, BChir, MRCP, discusses the potential role of PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer, highlighting radiographic PFS benefits from the PSMAddition trial while emphasizing the need to balance...
Praful Ravi, MB, BChir, MRCP,...
02/12/2026
Radiopharmaceutical Education Institute

Neuroendocrine Tumors (NETs)

News
177Lu-Edotreotide Extends Progression-Free Survival vs Everolimus in GEP-NETs
10/28/2025
Janelle Bradley
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly improved progression-free survival and objective response rates compared to everolimus in patients with advanced GEP-NETs, with consistent benefits across tumor grades, sites, and prior treatment settings,...
¹⁷⁷Lu-edotreotide significantly...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Demonstrates Promising Activity After Prior PRRT in Advanced GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE achieved a 30.8% objective response rate and a 96% disease control rate with a manageable safety profile in patients with advanced SSTR-positive GEP-NETs who had progressed following prior...
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
212Pb-DOTAMTATE Yields Durable and Deep Responses in PRRT-Naïve GEP-NETs
10/28/2025
Janelle Bradley
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02 trial, 212Pb-DOTAMTATE produced a 57% objective response rate and durable disease control with a favorable safety profile in PRRT-naïve patients with advanced somatostatin receptor-positive GEP-NETs.
In the phase 2 ALPHAMEDIX 02...
10/28/2025
Radiopharmaceutical Education Institute
News
Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors
04/24/2024
Stephanie Holland
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Based on results from the...
04/24/2024
Oncology
Conference Coverage
Randomized Study Demonstrates Efficacy of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors
01/19/2024
Stephanie Holland
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...
According to primary analysis...
01/19/2024
Oncology

Prostate Cancer

Kim Chi, MD
Videos
PR21 PLUTO Supports Flexible Sequencing of Docetaxel and Lutetium-177 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
Kim Chi, MD
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover analysis results from the PR21 PLUTO trial showing that patients with PSMA-positive metastatic castration-resistant prostate cancer experienced similar progression-free and overall survival outcomes regardless...
Kim Chi, MD, discusses crossover...
06/19/2026
Radiopharmaceutical Education Institute
David Cade, MD
Videos
TLX591 Shows Prolonged Tumor Retention With Limited Off-Target Radiation Exposure in Metastatic Castration-Resistant Prostate Cancer
06/19/2026
David Cade, MD
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the phase 3 PROSTACT Global trial evaluating TLX591, a PSMA-targeted radio-antibody drug conjugate that demonstrated favorable safety, dosimetry, and tumor-retention characteristics and is being developed for...
David Cade, MD, discusses the...
06/19/2026
Radiopharmaceutical Education Institute
Michael Morris, MD
Videos
Convo-1α Produces Durable Responses in Patients Previously Treated With PSMA Radioligand Therapy
06/18/2026
Michael Morris, MD
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses results from a phase 2 study showing that the actinium-225 PSMA-targeted radio-antibody conjugate Convo-1α achieved durable responses lasting up to 12 months with limited xerostomia and no nephrotoxicity in...
Michael Morris, MD, discusses...
06/18/2026
Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Approval
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute

Register for Our Events!

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use